NCT06152809 2026-03-18
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
Clinical Trials
15 trialsNCT06138587 2026-01-02
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT02763475 2020-10-05
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Instituto de Investigación Hospital Universitario La Paz
Phase 2 Completed
NCT00952237 2018-04-25
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT00274846 2017-12-28
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00354172 2017-12-28
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00625729 2017-12-28
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 1/2 Terminated
NCT00871689 2017-12-28
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01347996 2017-11-29
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Cytovia, Inc.
Phase 4 Completed
NCT01517347 2016-10-24
Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation
Peking University People's Hospital
Phase NA Terminated
NCT01390402 2016-02-03
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00402558 2015-05-08
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00187096 2014-06-19
Natural Killer (NK) Cell Transplantation for AML
St. Jude Children's Research Hospital
Phase NA Completed
NCT00941928 2014-05-22
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Terminated